MET and cancer: Foretinib (EXEL-2880, GSK1363089), a c-Met and VEGFR2 inhibitor, has demonstrated a high level of efficacy in clinical trials for other cancer types (NCT00742131, NCT00742261, NCT00743067), and in preclinical studies.